Acquired Company
SAB Biotherapeutics completed its merger with Big Cypress Acquisition Corp. on October 22, 2021, and the combined company began trading as SAB Biotherapeutics, Inc. on Nasdaq under the ticker SABS.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. Show more
777 W 41st St., Miami Beach, FL, 33140, United States
Start AI Chat
Market Cap
174.7M
52 Wk Range
$1.00 - $6.60
Previous Close
$3.67
Open
$3.66
Volume
582,239
Day Range
$3.62 - $3.87
Enterprise Value
21.63M
Cash
110.9M
Avg Qtr Burn
-13.05M
Insider Ownership
12.36%
Institutional Own.
82.61%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
SAB-142 Details Stage 3 Type 1 Diabetes (T1D) | Phase 2b Data readout |